RCKT ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Rocket

Levi & Korsinsky, LLP has recently initiated a securities fraud class action lawsuit against Rocket Pharmaceuticals, Inc., with a deadline of August 11, 2025. The lawsuit alleges that Rocket Pharmaceuticals made false and misleading statements that led to inflated stock prices. Investors who suffered losses due to these alleged actions are encouraged to join the lawsuit before the deadline.

According to the lawsuit filed by Levi & Korsinsky, Rocket Pharmaceuticals engaged in deceptive practices by providing false information to investors. These actions allegedly caused the company’s stock prices to rise artificially, leading investors to suffer financial losses when the truth was revealed. The class action lawsuit aims to hold Rocket Pharmaceuticals accountable for these alleged fraudulent activities.

Investors who purchased Rocket Pharmaceuticals stocks between September 25, 2019, and May 17, 2021, are eligible to join the class action lawsuit. The deadline to join the lawsuit is August 11, 2025. By participating in the lawsuit, investors may be able to recover some or all of their losses incurred due to the alleged securities fraud committed by Rocket Pharmaceuticals.

Levi & Korsinsky, LLP is a renowned law firm specializing in securities litigation. The firm has a track record of successfully representing investors in similar cases of securities fraud. By initiating the class action lawsuit against Rocket Pharmaceuticals, Levi & Korsinsky aims to seek justice for investors who suffered financial losses as a result of the alleged misleading statements made by the company.

Investors who wish to join the class action lawsuit against Rocket Pharmaceuticals are advised to act promptly and seek legal counsel. By participating in the lawsuit before the August 11, 2025 deadline, investors can potentially recover damages resulting from the alleged securities fraud committed by the company. Levi & Korsinsky is dedicated to representing the interests of investors and holding companies accountable for fraudulent practices that harm shareholders.